Европейски съюз - български - EMA (European Medicines Agency)

novartis europharm limited - asciminib hydrochloride - Левкемия, миелогенна, хронична, bcr-abl положителна - Антинеопластични средства - scemblix is indicated for the treatment of adult patients with philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (ph+ cml cp) previously treated with two or more tyrosine kinase inhibitors (see section 5.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - дазатиниб - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Антинеопластични средства - dasatinib accord is indicated for the treatment of adult patients with:• ph+ acute lymphoblastic leukaemia (all) with resistance or intolerance to prior therapy. dasatinib accord is indicated for the treatment of paediatric patients with:• newly diagnosed ph+ all in combination with chemotherapy.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - дазатиниб - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - Антинеопластични средства - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Европейски съюз - български - EMA (European Medicines Agency)

accord healthcare s.l.u. - сунитиниб - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - Антинеопластични средства - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.

Европейски съюз - български - EMA (European Medicines Agency)

ab science s.a. - masitinib mesilate - Антинеопластични средства - Кучета - Лечение на нерезрективни куче мастоцитни тумори (степен 2 или 3) с потвърден мутирал c-kit тирозин-киназен рецептор.

Европейски съюз - български - EMA (European Medicines Agency)

pfizer europe ma eeig  - акситиниб - Карцином, бъбречна клетка - Инхибитори на протеинкиназы - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Европейски съюз - български - EMA (European Medicines Agency)

ab science - masitinib mesilate - Амиотрофична латерална склероза - Антинеопластични средства - Лечение на страничните амиотрофического склероза.

Европейски съюз - български - EMA (European Medicines Agency)

ab science - masitinib mesilate - Мастоцитозата - Антинеопластични средства - Лечение мастоцитоза.

Европейски съюз - български - EMA (European Medicines Agency)

ab science - masitinib - Панкреатични неоплазми - Инхибитори на протеинкиназы - Лечение неоперабельной локално-напреднал или метастазирал рак на панкреаса .

Европейски съюз - български - EMA (European Medicines Agency)

masitinib - Стомашно-чревни стромални тумори - Инхибитори на протеинкиназы - Лечение неоперабельной и/или метастатичен злокачествен стромальной ЧРЕВНИ тумори (Гист).